about programs-policies political-partnerships 
FDA Law Blog
APRIL 8, 2024
Department of Health and Human Services (HHS) recently published a White Paper on Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States —with input from several HHS stakeholders, including FDA, CMS, and the Administration for Strategic Preparedness and Response. By Kalie E.
The Pharma Data
JULY 21, 2021
Leaders from these companies, organizations, and learning institutions have signed a pledge to co-develop programs focused on building trust in the health care system with communities of color and making measurable progress towards health equity. Enabling the next generation of Black and African American leaders.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
SEPTEMBER 16, 2020
” Learn more about Amgen ‘s development of innovative medicines for novel targets in difficult-to-treat solid tumors at AmgenOncology.com. To learn more about Amgen’s innovative pipeline with diverse modalities and genetically validated targets, please visit www.AmgenOncology.com. 20, 2020 , from 2:25 p.m. –
The Pharma Data
SEPTEMBER 20, 2020
About KRAS The RAS gene family, which has been the subject of almost four decades of research, contains some of the most frequently mutated oncogenes in human cancers. About KRAS The RAS gene family, which has been the subject of almost four decades of research, contains some of the most frequently mutated oncogenes in human cancers.
The Pharma Data
NOVEMBER 9, 2020
About Tezepelumab Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Amgen will record sales in the U.S. Outside the U.S.,
The Pharma Data
DECEMBER 21, 2020
About Tezepelumab Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Amgen will record sales in the U.S. Outside the U.S.,
Drug Discovery World
AUGUST 7, 2023
DDW’s Reece Armstrong speaks to Shantanu Dhamija , VP of Strategy and Innovation at Molecular Devices about challenges of diversity in clinical trials and why induced pluripotent stem cells might be key to representing wider patient groups. RA: Why is US clinical trial diversity at its lowest point in the last 10 years? Hispanic, 12.4%
Expert insights. Personalized for you.
59 
Let's personalize your content